Cargando…

Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors

OBJECTIVE: This study was conducted to characterize the effects of food on single-dose pharmacokinetics (PK) of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors. METHODS: Following overnight fasting for 10 h, a single 50 mg enteric-coated table...

Descripción completa

Detalles Bibliográficos
Autores principales:	Falchook, Gerald S., Zhou, Xiaofei, Venkatakrishnan, Karthik, Kurzrock, Razelle, Mahalingam, Devalingam, Goldman, Jonathan W., Jung, JungAh, Ullmann, Claudio Dansky, Milch, Catherine, Rosen, Lee S., Sarantopoulos, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2015
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767718/ https://www.ncbi.nlm.nih.gov/pubmed/26689566 http://dx.doi.org/10.1007/s40268-015-0114-8

Ejemplares similares

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors
por: Sells, Todd B., et al.
Publicado: (2015)

An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes
por: Goldberg, Stuart L., et al.
Publicado: (2014)

A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
por: Gay, Carl M., et al.
Publicado: (2020)

The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib
por: Kelly, Kevin R, et al.
Publicado: (2011)

MLN-8237: A dual inhibitor of aurora A and B in soft tissue sarcomas
por: Nair, Jayasree S., et al.
Publicado: (2016)

Development of an intravaginal ring for the topical delivery of Aurora kinase A inhibitor, MLN8237
por: Tayyar, Yaman, et al.
Publicado: (2019)

Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2017)

Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2017)

A Novel Aurora-A Inhibitor (MLN8237) Synergistically Enhances the Antitumor Activity of Sorafenib in Hepatocellular Carcinoma
por: Zhang, Kai, et al.
Publicado: (2018)

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer
por: Carol, Hernan, et al.
Publicado: (2011)

The Aurora-A inhibitor MLN8237 affects multiple mitotic processes and induces dose-dependent mitotic abnormalities and aneuploidy
por: Asteriti, Italia Anna, et al.
Publicado: (2014)

The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G(2)/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells
por: Li, Jin-Ping, et al.
Publicado: (2015)

Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia
por: Kelly, Kevin R., et al.
Publicado: (2013)

Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia
por: Zhou, Xiaofei, et al.
Publicado: (2017)

Silencing of AURKA augments the antitumor efficacy of the AURKA inhibitor MLN8237 on neuroblastoma cells
por: Yang, Yan, et al.
Publicado: (2020)

Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway
por: Niu, Ning-Kui, et al.
Publicado: (2015)

Population Pharmacokinetics and Exposure‐Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2022)

ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib
por: Michaelis, Martin, et al.
Publicado: (2015)

Cisplatin‐resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib
por: Wang, Lihong, et al.
Publicado: (2017)

Domain-specific interactions between MLN8237 and human serum albumin estimated by STD and WaterLOGSY NMR, ITC, spectroscopic, and docking techniques
por: Yang, Hongqin, et al.
Publicado: (2017)

Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor
por: Niu, Huifeng, et al.
Publicado: (2017)

Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer
por: Niu, Huifeng, et al.
Publicado: (2015)

Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer
por: Pitts, Todd M., et al.
Publicado: (2016)

Alisertib promotes apoptosis and autophagy in melanoma through p38 MAPK-mediated aurora a signaling
por: Shang, Yuan-Yuan, et al.
Publicado: (2017)

Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
por: O’Connor, Owen A., et al.
Publicado: (2019)

Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia
por: Fathi, Amir T., et al.
Publicado: (2017)

Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells
por: Yuan, Chun-Xiu, et al.
Publicado: (2015)

Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells
por: Ding, Yong-Hui, et al.
Publicado: (2015)

Inhibition of Aurora Kinase A by Alisertib Reduces Cell Proliferation and Induces Apoptosis and Autophagy in HuH-6 Human Hepatoblastoma Cells
por: Tan, Jingyi, et al.
Publicado: (2020)

Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors
por: Zhou, Xiaofei, et al.
Publicado: (2022)

Combining selinexor with alisertib to target the p53 pathway in neuroblastoma
por: Nguyen, Rosa, et al.
Publicado: (2022)

Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer
por: Patel, Sukeshi, et al.
Publicado: (2016)

A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma
por: Mahalingam, Devalingam, et al.
Publicado: (2019)

Antitumor Effect of Lenvatinib Combined with Alisertib in Hepatocellular Carcinoma by Targeting the DNA Damage Pathway
por: Hao, Jianwen, et al.
Publicado: (2021)

Crosstalk of RNA methylation writers defines tumor microenvironment and alisertib resistance in breast cancer
por: Zhang, Xiaoqiang, et al.
Publicado: (2023)

Alisertib exerts KRAS allele‑specific anticancer effects on colorectal cancer cell lines
por: Ren, Baojun, et al.
Publicado: (2023)

Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors
por: Naing, Aung, et al.
Publicado: (2013)

Review: Oncolytic virotherapy, updates and future directions
por: Fountzilas, Christos, et al.
Publicado: (2017)

The Landscape of Targeted Therapies in TNBC
por: Vagia, Elena, et al.
Publicado: (2020)

Sustained and durable response with Alisertib monotherapy in the treatment of relapsed Atypical Teratoid Rhabdoid Tumor (ATRT)
por: Howden, Kaitlyn, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ft6vqdp6ccr92gbqaqjc14jvg9